<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC3358196/results/search/disease/results.xml">
  <result pre="courier ; font-style : italic;} Emerg Infect DisEmerging Infect. DisEIDEmerging" exact="Infectious" post="Diseases1080-60401080-6059Centers for Disease Control and Prevention pmcid: 3358196 pmid:"/>
  <result pre=": italic;} Emerg Infect DisEmerging Infect. DisEIDEmerging Infectious Diseases1080-60401080-6059Centers for" exact="Disease" post="Control and Prevention pmcid: 3358196 pmid: 2174975910-1161 doi: 10.3201/eid1706.101161"/>
  <result pre="UK; email: richard.pebody@hpa.org.uk ppub: 2011-6176990999 TOC Summary: Early treatment of" exact="primary" post="case-patients and prophylaxis of household contacts provides effective protection."/>
  <result pre="effect of AVs on household transmission. We followed 285 confirmed" exact="primary" post="cases in 259 households with 761 contacts. At 2"/>
  <result pre="259 households with 761 contacts. At 2 weeks, the confirmed" exact="secondary" post="attack rate (SAR) was 8.1% (62/761) and significantly higher"/>
  <result pre="age (18.9% vs. 1.2%, p&amp;lt;0.001). Early (&amp;lt;48 hours) treatment of" exact="primary" post="case-patients reduced SAR (4.5% vs. 10.6%, p = 0.003)."/>
  <result pre="The SAR in child contacts was 33.3% (10/30) when the" exact="primary" post="contact was a woman and 2.9% (1/34) when the"/>
  <result pre="primary contact was a woman and 2.9% (1/34) when the" exact="primary" post="contact was a man (p = 0.010). Of 53"/>
  <result pre="contact was a man (p = 0.010). Of 53 confirmed" exact="secondary" post="case-patients, 45 had not received AV prophylaxis. The effectiveness"/>
  <result pre="received AV prophylaxis. The effectiveness of AV prophylaxis in preventing" exact="infection" post="was 92%. Keywords: viruses influenza pandemic prophylaxis pandemic (H1N1)"/>
  <result pre="transmissibility of the virus in household settings. Household-based studies of" exact="avian influenza" post="previously provided a measure of transmissibility of newly emerging"/>
  <result pre="where AVs were not used (8,10) or where only a" exact="limited" post="number of households were recruited (7,9), early work suggests"/>
  <result pre="contacts to determine key parameters such as virologic and clinical" exact="secondary" post="attack rates (SARs) and effectiveness of AVs. Definitions Three"/>
  <result pre="(H1N1) 2009 virus by specific reverse transcription PCR (RT-PCR) on" exact="respiratory" post="swab; 2) influenza-like illness (ILI) cases were persons experiencing"/>
  <result pre="(ILI) cases were persons experiencing history of fever and &amp;gt;1" exact="respiratory" post="symptom (dry cough, productive cough, coryza, shortness of breath,"/>
  <result pre="sneezing) within 2 weeks of onset of the confirmed household" exact="primary" post="case; and 3) acute respiratory infection (ARI) cases were"/>
  <result pre="of onset of the confirmed household primary case; and 3)" exact="acute" post="respiratory infection (ARI) cases were persons experiencing &amp;gt;1 respiratory"/>
  <result pre="onset of the confirmed household primary case; and 3) acute" exact="respiratory" post="infection (ARI) cases were persons experiencing &amp;gt;1 respiratory symptom"/>
  <result pre="of the confirmed household primary case; and 3) acute respiratory" exact="infection" post="(ARI) cases were persons experiencing &amp;gt;1 respiratory symptom (as"/>
  <result pre="3) acute respiratory infection (ARI) cases were persons experiencing &amp;gt;1" exact="respiratory" post="symptom (as defined above) and/or fever within 2 weeks"/>
  <result pre="fever within 2 weeks of onset of the confirmed household" exact="primary" post="case. A household contact was any person who lived"/>
  <result pre="person who lived in the same household as a confirmed" exact="primary" post="case-patient and &amp;gt;1 overnight stay after onset of illness"/>
  <result pre="after onset of illness in the person who was the" exact="primary" post="case-patient (16). A household was defined as the primary"/>
  <result pre="the primary case-patient (16). A household was defined as the" exact="primary" post="case-patient plus all household contacts. For a household, a"/>
  <result pre="plus all household contacts. For a household, a virologically confirmed" exact="primary" post="case was the case-patient with first date of onset"/>
  <result pre="case-patient with first date of onset within that household. A" exact="secondary" post="case was any case-patient with date of onset &amp;gt;24"/>
  <result pre="date of onset &amp;gt;24 hours after date of onset of" exact="primary" post="case. If a patientâ€™s onset of illness was &amp;lt;24"/>
  <result pre="onset of illness was &amp;lt;24 hours of onset of the" exact="primary" post="case, it was classified as co-primary. A similar approach"/>
  <result pre="as co-primary. A similar approach was followed for clinically confirmed" exact="secondary" post="cases, with clinical co-primary cases excluded. Secondary cases were"/>
  <result pre="for clinically confirmed secondary cases, with clinical co-primary cases excluded." exact="Secondary" post="cases were defined as case-patients who had received prophylaxis"/>
  <result pre="interview, contacts were asked about their contact history with the" exact="primary" post="case-patient; clinical history, including recent respiratory symptoms with dates"/>
  <result pre="contact history with the primary case-patient; clinical history, including recent" exact="respiratory" post="symptoms with dates of onset and treatment; medical history,"/>
  <result pre="follow-up of contacts was undertaken for 7 days. If any" exact="respiratory" post="symptoms developed, contacts were instructed to speak to their"/>
  <result pre="to their general practitioners for prompt investigation, including collection of" exact="respiratory" post="swab specimens. Swab samples were also inadvertently obtained from"/>
  <result pre="through standard data entry checks, double entry, and internal and" exact="external" post="consistency checks. Statistical Analysis Single-person households were excluded from"/>
  <result pre="confirmed infection. The cumulative household SAR was defined as the" exact="total" post="number of secondary cases in a household divided by"/>
  <result pre="cumulative household SAR was defined as the total number of" exact="secondary" post="cases in a household divided by number of household"/>
  <result pre="household divided by number of household members at risk (excluding" exact="primary" post="and co-primary cases) 14 days after onset in the"/>
  <result pre="primary and co-primary cases) 14 days after onset in the" exact="primary" post="case-patient. Household SAR was calculated by age group (&amp;lt;16"/>
  <result pre="prophylaxis (yes or no), and timing of treatment for the" exact="primary" post="case-patient (&amp;lt;48 hours vs. &amp;gt;48 hours) through univariate logistic"/>
  <result pre="SAR may be affected by failure to obtain swabs from" exact="symptomatic" post="contacts, observed positivity rates in the ARI and nonsymptomatic"/>
  <result pre="onset, and survival time is defined up until onset of" exact="disease" post="in the contact (failure), or excluded at the end"/>
  <result pre="and AV prophylaxis periods. The hazard ratio of becoming a" exact="secondary" post="case-patient when AV prophylaxis was given was estimated by"/>
  <result pre="regression, adjusted for age, sex, and AV treatment of the" exact="primary" post="case-patient &amp;lt;48 hours. This approach accounted for prophylaxis not"/>
  <result pre="until the case-patient was identified by health services. Laboratory Confirmation" exact="Respiratory" post="samples from influenza patients were analyzed for pandemic influenza"/>
  <result pre="influenza A (H1N1) 2009 and seasonal influenza viruses by RT-PCR." exact="Combined" post="nose and throat swab specimens were collected from patients"/>
  <result pre="data by NHS and data processing data by HPA for" exact="communicable disease" post="control. Health Protection Scotland remains embedded as part of"/>
  <result pre="by NHS and data processing data by HPA for communicable" exact="disease" post="control. Health Protection Scotland remains embedded as part of"/>
  <result pre="of national outbreaks. Results Recruitment and Follow-up of Households A" exact="total" post="of 322 confirmed primary and co-primary case-patients were identified"/>
  <result pre="Recruitment and Follow-up of Households A total of 322 confirmed" exact="primary" post="and co-primary case-patients were identified in 296 households (Figure"/>
  <result pre="0.092). Single-person households were excluded from further analysis, leaving 259" exact="primary" post="and 26 co-primary case-patients in 259 households (Figure 1)."/>
  <result pre="pandemic (H1N1) 2009 case-patients and household contacts, including contacts with" exact="respiratory" post="symptoms, contacts from whom swab specimens were collected, and"/>
  <result pre="swabs taken &amp;gt;2 weeks after index case-patient symptom onset. The" exact="total" post="number of household contacts identified was 866. Of these,"/>
  <result pre="between those followed and not followed-up. Distribution of household sizes," exact="primary" post="cases, contacts, and secondary cases is shown in Table"/>
  <result pre="not followed-up. Distribution of household sizes, primary cases, contacts, and" exact="secondary" post="cases is shown in Table 1. Table 1 Household"/>
  <result pre="Table 1 Household size of case-patients with pandemic (H1N1) 2009" exact="virus infection," post="United Kingdom, 2009 No. persons in household No. households"/>
  <result pre="United Kingdom, 2009 No. persons in household No. households No." exact="primary" post="and co-primary case patients No. contacts No. secondary case-patients"/>
  <result pre="households No. primary and co-primary case patients No. contacts No." exact="secondary" post="case-patients 2 42 44 40 2 3 46 51"/>
  <result pre="11 2 2 20 2 15 1 1 14 3" exact="Total" post="240 266 761 62 Household and Primary Case-Patient Characteristics"/>
  <result pre="1 14 3 Total 240 266 761 62 Household and" exact="Primary" post="Case-Patient Characteristics Average household size was 4 people (SD"/>
  <result pre="1). A comparison of age, gender, and AV use of" exact="primary" post="case-patients, co-primary case-patients, and contacts is provided in Table"/>
  <result pre="case-patients, and contacts is provided in Table 2. Table 2" exact="Primary" post="and co-primary confirmed case-patients with pandemic (H1N1) 2009 virus"/>
  <result pre="2 Primary and co-primary confirmed case-patients with pandemic (H1N1) 2009" exact="virus infection" post="and household contacts, by sex, age, and prophylaxis status,"/>
  <result pre="Primary and co-primary confirmed case-patients with pandemic (H1N1) 2009 virus" exact="infection" post="and household contacts, by sex, age, and prophylaxis status,"/>
  <result pre="age, and prophylaxis status, United Kingdom, 2009* Variable No. (%)" exact="primary" post="and co-primary case-patients No. (%) contacts Sex, n ="/>
  <result pre="No 253 (98.8) 132 (22.5) Yes 3 (1.2) 455 (77.5)" exact="Total" post="285 761 *n = 1,046 except as indicated. Of"/>
  <result pre="285 761 *n = 1,046 except as indicated. Of the" exact="primary" post="case-patients, 245 (95.7%) had received AV treatment (of whom"/>
  <result pre="treated case-patients, 104 (42.4%) had started treatment &amp;lt;48 hours of" exact="disease" post="onset, with median time to AV treatment of 3"/>
  <result pre="received oseltamivir. Mean number of days from onset in the" exact="primary" post="case-patient to starting prophylaxis in contacts was 4.4 days"/>
  <result pre="&amp;lt;5 days. Table 3 Confirmed SAR of pandemic (H1N1) 2009" exact="virus infection," post="according to time antiviral drug prophylaxis began after onset"/>
  <result pre="time antiviral drug prophylaxis began after onset of illness in" exact="primary" post="case-patient, plus timing of secondary cases after onset of"/>
  <result pre="after onset of illness in primary case-patient, plus timing of" exact="secondary" post="cases after onset of primary case, United Kingdom, 2009*"/>
  <result pre="primary case-patient, plus timing of secondary cases after onset of" exact="primary" post="case, United Kingdom, 2009* Timing No. contacts No. secondary"/>
  <result pre="of primary case, United Kingdom, 2009* Timing No. contacts No." exact="secondary" post="case-patients at 14 d SAR, % (95% CI) No."/>
  <result pre="case-patients at 14 d SAR, % (95% CI) No. (%)" exact="secondary" post="case-patients 2 d 3â€“4 d 5â€“7 d &amp;gt;7 d"/>
  <result pre="&amp;gt;7 d 92 0 0.0 (0.0-3.9) NA NA NA 0" exact="Total" post="case-patients 587 53 9.0 (6.8â€“11.7) 15 (2.6) 15 (2.6)"/>
  <result pre="(6.8â€“11.7) 15 (2.6) 15 (2.6) 15 (2.6) 8 (1.4) *SAR," exact="secondary" post="attack rate; CI, confidence interval; NA, not applicable. Figure"/>
  <result pre="applicable. Figure 2 Days from symptom onset date of household" exact="primary" post="case-patient with pandemic (H1N1) 2009 virus infection until antiviral"/>
  <result pre="onset date of household primary case-patient with pandemic (H1N1) 2009" exact="virus infection" post="until antiviral prophylaxis started, N = 352, United Kingdom,"/>
  <result pre="date of household primary case-patient with pandemic (H1N1) 2009 virus" exact="infection" post="until antiviral prophylaxis started, N = 352, United Kingdom,"/>
  <result pre="antiviral prophylaxis started, N = 352, United Kingdom, 2009. Household" exact="Secondary" post="Attack Rates Household contacts in whom respiratory symptoms developed"/>
  <result pre="prophylaxis started, N = 352, United Kingdom, 2009. Household Secondary" exact="Attack" post="Rates Household contacts in whom respiratory symptoms developed within"/>
  <result pre="Kingdom, 2009. Household Secondary Attack Rates Household contacts in whom" exact="respiratory" post="symptoms developed within 2 weeks and from whom swab"/>
  <result pre="contacts, 166 had ARI symptoms, 62 of whom were confirmed" exact="secondary" post="case-patients, with a SAR of 8.1% (Table 4). Among"/>
  <result pre="Table 4 Univariate and multivariate analysis of pandemic (H1N1) 2009" exact="virus infection" post="SAR for virologically confirmed cases of pandemic (H1N1) 2009"/>
  <result pre="4 Univariate and multivariate analysis of pandemic (H1N1) 2009 virus" exact="infection" post="SAR for virologically confirmed cases of pandemic (H1N1) 2009"/>
  <result pre="infection SAR for virologically confirmed cases of pandemic (H1N1) 2009" exact="virus infection," post="by gender, age group, and prophylaxis, United Kingdom, 2009*"/>
  <result pre="baseline Yes 444 8 1.8 (0.8â€“3.9) &amp;lt;0.001 0.05 (0.02â€“0.09) &amp;lt;0.001" exact="Primary" post="case-patient treatment &amp;gt;48 h 453 48 10.6 (8.1â€“13.8) 1.0,"/>
  <result pre="&amp;lt;48 h 308 14 4.5 (2.5â€“8.1) 0.003 0.30 (0.13â€“0.68) 0.004" exact="Total" post="761 62 8.1 (6.4â€“10.3) *n = 761 except as"/>
  <result pre="Hosmer-Lemeshow goodness-of-fit test for multivariate model, p = 0.751. SAR," exact="secondary" post="attack rate; CI, confidence interval; OR, odds ratio.â€¨â€ Excludes co-primary"/>
  <result pre="&amp;gt;50 years. The SAR in male patients was higher than" exact="female" post="patients, but the difference was not significant (Table 4)."/>
  <result pre="patients, but the difference was not significant (Table 4). Most" exact="secondary" post="case-patients (86.8%, 45/53) had not received prophylaxis; contacts who"/>
  <result pre="Contacts who received prophylaxis &amp;lt;2 days after onset in the" exact="primary" post="case-patient had a nonsignificantly higher SAR than those who"/>
  <result pre="power to detect such differences. The confirmed SAR was significantly" exact="lower" post="in contacts whose primary case-patient had received treatment &amp;lt;48"/>
  <result pre="differences. The confirmed SAR was significantly lower in contacts whose" exact="primary" post="case-patient had received treatment &amp;lt;48 hours of onset rather"/>
  <result pre="48 hours (Table 4). The confirmed SAR by age of" exact="primary" post="case-patients is shown in Table 5. Confirmed SAR was"/>
  <result pre="was high among those &amp;lt;16 years of age, whether the" exact="primary" post="case-patient was a child or an adult. Similarly, SAR"/>
  <result pre="an adult. Similarly, SAR was low among adults, whether the" exact="primary" post="case-patient was a child or an adult (Table 5)."/>
  <result pre="adults, whether the primary case-patient was a child or an" exact="adult" post="(Table 5). When transmission from adults to children was"/>
  <result pre="found for SARs in children according to sex of the" exact="adult" post="primary case-patient: 33.3% (10/30, 95% confidence interval [CI] 17.3â€“52.8)"/>
  <result pre="for SARs in children according to sex of the adult" exact="primary" post="case-patient: 33.3% (10/30, 95% confidence interval [CI] 17.3â€“52.8) for"/>
  <result pre="primary case-patient: 33.3% (10/30, 95% confidence interval [CI] 17.3â€“52.8) for" exact="female" post="primary case-patients and 2.9% (1/34, 95% CI 0.1â€“15.3) for"/>
  <result pre="case-patient: 33.3% (10/30, 95% confidence interval [CI] 17.3â€“52.8) for female" exact="primary" post="case-patients and 2.9% (1/34, 95% CI 0.1â€“15.3) for men"/>
  <result pre="CI 2.0â€“138.8; p = 0.010). Table 5 Pandemic (H1N1) 2009" exact="virus infection" post="SAR, by age of patient with virologically confirmed primary"/>
  <result pre="2.0â€“138.8; p = 0.010). Table 5 Pandemic (H1N1) 2009 virus" exact="infection" post="SAR, by age of patient with virologically confirmed primary"/>
  <result pre="virus infection SAR, by age of patient with virologically confirmed" exact="primary" post="case, United Kingdom, 2009* Transmissionâ€  No. contacts No. secondaryâ€¨case-patients"/>
  <result pre="CI) Child to child 148 29 19.6 (13.5â€“26.9) Child to" exact="adult" post="318 9 2.8 (1.3â€“5.3) Adult to adult 231 13"/>
  <result pre="29 19.6 (13.5â€“26.9) Child to adult 318 9 2.8 (1.3â€“5.3)" exact="Adult" post="to adult 231 13 5.6 (3.0â€“9.4) Adult to child"/>
  <result pre="(13.5â€“26.9) Child to adult 318 9 2.8 (1.3â€“5.3) Adult to" exact="adult" post="231 13 5.6 (3.0â€“9.4) Adult to child 64 11"/>
  <result pre="9 2.8 (1.3â€“5.3) Adult to adult 231 13 5.6 (3.0â€“9.4)" exact="Adult" post="to child 64 11 17.2 (8.9â€“Â­28.7) *SAR, secondary attack"/>
  <result pre="5.6 (3.0â€“9.4) Adult to child 64 11 17.2 (8.9â€“Â­28.7) *SAR," exact="secondary" post="attack rate; CI, confidence interval.â€¨â€ Primary case-patient to contact. Multivariate"/>
  <result pre="Multivariate analysis shows the adjusted odds for a virologically confirmed" exact="secondary" post="case were significantly higher for children &amp;lt;16 years of"/>
  <result pre="received AV prophylaxis had a significantly reduced risk of confirmed" exact="infection" post="than those not treated (Table 4). Finally, the adjusted"/>
  <result pre="not treated (Table 4). Finally, the adjusted odds of a" exact="secondary" post="case-patient were significantly lower when the primary case-patient had"/>
  <result pre="Finally, the adjusted odds of a secondary case-patient were significantly" exact="lower" post="when the primary case-patient had received treatment &amp;lt;48 hours"/>
  <result pre="odds of a secondary case-patient were significantly lower when the" exact="primary" post="case-patient had received treatment &amp;lt;48 hours of onset. SAR"/>
  <result pre="an additional 16 cases defined as co-primaries. Seventy-eight clinically confirmed" exact="secondary" post="cases occurred among 745 contacts for an overall household"/>
  <result pre="Table 6 Univariate and multivariate analysis of pandemic (H1N1) 2009" exact="virus infection" post="SAR for clinically confirmed cases of influenza-like illness, by"/>
  <result pre="6 Univariate and multivariate analysis of pandemic (H1N1) 2009 virus" exact="infection" post="SAR for clinically confirmed cases of influenza-like illness, by"/>
  <result pre="baseline Yes 444 18 4.1 (2.3â€“7.1) &amp;lt;0.001 0.05 (0.02â€“0.09) &amp;lt;0.001" exact="Primary" post="case-patient treatment &amp;gt;48 h 445 55 12.4 (9.6â€“15.8) 1.0,"/>
  <result pre="&amp;lt;48 h 300 23 7.7 (4.7â€“12.2) 0.040 0.78 (0.42â€“1.48) 0.458" exact="Total" post="745 78 10.5 (8.5â€“12.9) *n = 745 except as"/>
  <result pre="Hosmer-Lemeshow goodness-of-fit test for multivariable model, p = 0.291. SAR," exact="secondary" post="attack rate; CI, confidence interval; OR, odds ratio.â€¨â€ Excludes co-primary"/>
  <result pre="as co-primaries. In the 259 households, of 719 contacts, 120" exact="secondary" post="case-patients resulted for an ARI SAR of 16.7% (Table"/>
  <result pre="7 Univariate and multivariate analysis of pandemic (H1N1) 2009 SAR" exact="infection" post="for acute respiratory infection, by gender, age group and"/>
  <result pre="and multivariate analysis of pandemic (H1N1) 2009 SAR infection for" exact="acute" post="respiratory infection, by gender, age group and prophylaxis, United"/>
  <result pre="multivariate analysis of pandemic (H1N1) 2009 SAR infection for acute" exact="respiratory" post="infection, by gender, age group and prophylaxis, United Kingdom,"/>
  <result pre="baseline Yes 443 34 7.7 (4.5â€“12.7) &amp;lt;0.001 0.02 (0.01â€“0.03) &amp;lt;0.001" exact="Primary" post="case-patient treatment &amp;gt;48 h 435 79 18.2 (14.8â€“22.1) 1,"/>
  <result pre="&amp;lt;48 h 284 41 14.4 (10.1â€“20.3) 0.019 1.7 (0.9â€“3.1) 0.11" exact="Total" post="719 120 16.7 (14.1â€“19.6) *n = 719 except as"/>
  <result pre="Hosmer-Lemeshow goodness-of-fit test for multivariate model, p = 0.392. SAR," exact="secondary" post="attack rate; CI, confidence interval; OR, odds ratio.â€¨â€ Excludes coprimary"/>
  <result pre="of Prophylaxis The hazard ratio (HR) of becoming a confirmed" exact="secondary" post="case-patient when receiving AV drugs was 0.08 (95% CI"/>
  <result pre="Results were similar after adjusting for AV treatment of the" exact="primary" post="case-patient, age, and sex (HR 0.09, 95% CI 0.03â€“0.32)."/>
  <result pre="symptom onset in index case-patient until onset of symptoms in" exact="secondary" post="case-patients, United Kingdom, 2009. A) Virologically confirmed pandemic (H1N1)"/>
  <result pre="Virologically confirmed pandemic (H1N1) 2009; B) clinical influenza-like illness; C)" exact="acute" post="respiratory infection. Table 8 Multivariable survival analysis of for"/>
  <result pre="confirmed pandemic (H1N1) 2009; B) clinical influenza-like illness; C) acute" exact="respiratory" post="infection. Table 8 Multivariable survival analysis of for pandemic"/>
  <result pre="Table 8 Multivariable survival analysis of for pandemic (H1N1) 2009" exact="virus infection" post="SAR with virologic, influenza-like-illness, and acute respiratory infection endpoints,"/>
  <result pre="8 Multivariable survival analysis of for pandemic (H1N1) 2009 virus" exact="infection" post="SAR with virologic, influenza-like-illness, and acute respiratory infection endpoints,"/>
  <result pre="pandemic (H1N1) 2009 virus infection SAR with virologic, influenza-like-illness, and" exact="acute" post="respiratory infection endpoints, by gender, age group, and prophylaxis,"/>
  <result pre="(H1N1) 2009 virus infection SAR with virologic, influenza-like-illness, and acute" exact="respiratory" post="infection endpoints, by gender, age group, and prophylaxis, United"/>
  <result pre="2009 virus infection SAR with virologic, influenza-like-illness, and acute respiratory" exact="infection" post="endpoints, by gender, age group, and prophylaxis, United Kingdom,"/>
  <result pre="2009* Variable Hazard ratio (95% confidence interval) Virologic Influenza-like illness" exact="Acute" post="respiratory infection Sex M 1 (reference) 1 (reference) 1"/>
  <result pre="Variable Hazard ratio (95% confidence interval) Virologic Influenza-like illness Acute" exact="respiratory" post="infection Sex M 1 (reference) 1 (reference) 1 (reference)"/>
  <result pre="Hazard ratio (95% confidence interval) Virologic Influenza-like illness Acute respiratory" exact="infection" post="Sex M 1 (reference) 1 (reference) 1 (reference) F"/>
  <result pre="(reference) &amp;lt;48 h 0.45 (0.23â€“0.87) 0.72 (0.42â€“1.23) 0.99 (0.66â€“1.50) *SAR," exact="secondary" post="attack rate. In most households, either all members received"/>
  <result pre="among children. The SARs for child contacts were higher when" exact="adult" post="women were the primary case-patients than when men were."/>
  <result pre="for child contacts were higher when adult women were the" exact="primary" post="case-patients than when men were. Finally, most secondary case-patients"/>
  <result pre="were the primary case-patients than when men were. Finally, most" exact="secondary" post="case-patients had not received AV prophylaxis, and AV administration"/>
  <result pre="definition, a different period of follow-up, differences in ascertainment of" exact="secondary" post="cases, and differences in AV use. Our observed SAR"/>
  <result pre="Serologic studies will provide important insights into the rates of" exact="infection" post="(both symptomatic and asymptomatic in a household setting). Recent"/>
  <result pre="will provide important insights into the rates of infection (both" exact="symptomatic" post="and asymptomatic in a household setting). Recent publications have"/>
  <result pre="reduces SAR for all endpoints, updating earlier work (11). Most" exact="secondary" post="cases occurred in contacts who had not yet received"/>
  <result pre="yet received AV prophylaxis after onset of illness in the" exact="primary" post="case-patient, with a very high SAR observed in those"/>
  <result pre="household study, found that postexposure prophylaxis reduced the incidence of" exact="infection" post="in close household contacts by 89% (25). Our study"/>
  <result pre="before 1957 (29,30). This study found that SAR was significantly" exact="lower" post="when the primary case-patient had received rapid AV treatment,"/>
  <result pre="This study found that SAR was significantly lower when the" exact="primary" post="case-patient had received rapid AV treatment, before and after"/>
  <result pre="virus shedding (31). This may translate into reduced likelihood of" exact="secondary" post="transmission and supports rapid treatment of patients to reduce"/>
  <result pre="The observation that SARs from child to child and from" exact="adult" post="to child (&amp;gt;20%) were similar, yet at least 4-fold"/>
  <result pre="similar, yet at least 4-fold higher than from child to" exact="adult" post="or adult to adult, is also consistent with the"/>
  <result pre="at least 4-fold higher than from child to adult or" exact="adult" post="to adult, is also consistent with the increasing prevalence"/>
  <result pre="however, for adult-to-child transmission was just as high, particularly among" exact="female" post="primary case-patients, which suggests that despite lower virus titers"/>
  <result pre="for adult-to-child transmission was just as high, particularly among female" exact="primary" post="case-patients, which suggests that despite lower virus titers and"/>
  <result pre="high, particularly among female primary case-patients, which suggests that despite" exact="lower" post="virus titers and shorter duration of excretion, women transmitted"/>
  <result pre="and shorter duration of excretion, women transmitted pandemic (H1N1) 2009" exact="infection" post="as efficiently as child primary case-patients. This suggests adult"/>
  <result pre="women transmitted pandemic (H1N1) 2009 infection as efficiently as child" exact="primary" post="case-patients. This suggests adult respiratory hygiene is suboptimal in"/>
  <result pre="2009 infection as efficiently as child primary case-patients. This suggests" exact="adult" post="respiratory hygiene is suboptimal in the home environment. This"/>
  <result pre="infection as efficiently as child primary case-patients. This suggests adult" exact="respiratory" post="hygiene is suboptimal in the home environment. This study"/>
  <result pre="There are, however, limitations. First, not all those who had" exact="respiratory" post="symptoms develop had throat swabs done, leading to under-ascertainment"/>
  <result pre="develop had throat swabs done, leading to under-ascertainment of confirmed" exact="secondary" post="case-patients. Adjustments have been made to account for this."/>
  <result pre="finding was based on a screening algorithm requiring fever. Thus," exact="primary" post="cases of pandemic influenza without fever would have been"/>
  <result pre="have been excluded; however, all clinical endpoints were gathered from" exact="secondary" post="case-patients. Third, this article presents information only on clinical"/>
  <result pre="evidence that a substantial proportion of persons exposed to a" exact="primary" post="case-patient will have asymptomatic or very mildly symptomatic infection."/>
  <result pre="to a primary case-patient will have asymptomatic or very mildly" exact="symptomatic" post="infection. This requires serologic investigation (30). Fourth, because data"/>
  <result pre="(30). Fourth, because data were captured as part of the" exact="acute" post="public health response, data gathering was undertaken through multiple"/>
  <result pre="systematic bias that might invalidate the results. Fifth, if a" exact="primary" post="case-patient was confirmed quickly, their contacts may have avoided"/>
  <result pre="their contacts may have avoided further contact, whereas if the" exact="primary" post="case-patient was identified later, close contact may not have"/>
  <result pre="difference for contacts not receiving AV. Sixth, information concerning prior" exact="respiratory" post="disease in contacts was not gathered, and some persons"/>
  <result pre="for contacts not receiving AV. Sixth, information concerning prior respiratory" exact="disease" post="in contacts was not gathered, and some persons may"/>
  <result pre="been a major potential confounding factor. Finally, we assumed household" exact="secondary" post="case-patients acquired their infection after contact with a defined"/>
  <result pre="major potential confounding factor. Finally, we assumed household secondary case-patients" exact="acquired" post="their infection after contact with a defined primary case-patient"/>
  <result pre="confounding factor. Finally, we assumed household secondary case-patients acquired their" exact="infection" post="after contact with a defined primary case-patient in the"/>
  <result pre="secondary case-patients acquired their infection after contact with a defined" exact="primary" post="case-patient in the household, rather than in the community."/>
  <result pre="study was undertaken at a stage when community transmission was" exact="limited" post="so this contribution is assumed to be minimal. In"/>
  <result pre="higher than those of seasonal influenza. Timely AV treatment of" exact="primary" post="case-patients and prophylaxis was effective in protecting household contacts,"/>
  <result pre="spread. Prompt AV administration (either as treatment or prophylaxis) reduces" exact="symptomatic" post="SARs. Suggested citation for this article: Pebody RG, Harris"/>
  <result pre="An abstract was presented at the International Conference on Emerging" exact="Infectious" post="Diseases, Atlanta, Georgia, USA, 2010. Dr Pebody is a"/>
  <result pre="is responsible for influenza surveillance. His research interests include vaccine-preventable" exact="infections" post="with a focus on influenza epidemiology. References References 1."/>
  <result pre="focus on influenza epidemiology. References References 1. collab: Centers for" exact="Disease" post="Control and PreventionOutbreak of swine-origin influenza A (H1N1) virus"/>
  <result pre="2009.MMWR Morb Mortal Wkly Rep. 2009;58:467â€“7019444150 2. collab: Centers for" exact="Disease" post="Control and PreventionSwine influenza A (H1N1) infection in two"/>
  <result pre="collab: Centers for Disease Control and PreventionSwine influenza A (H1N1)" exact="infection" post="in two childrenâ€“Southern California, Marchâ€“April 2009.MMWR Morb Mortal Wkly"/>
  <result pre="Beest HolleM, MeijerA, KlinkenbergD, DonnellyCA, et al.Detecting emerging transmissibility of" exact="avian influenza" post="virus in human households.PLOS Comput Biol. 2007;3:e14510.1371/journal.pcbi.003014517676981 7. OdairaF,"/>
  <result pre="OdairaF, TakahashiH, ToyokawaT, TsuchihashiY, KodamaT, YahataY, et al. Assessment of" exact="secondary" post="attack rate and effectiveness of antiviral prophylaxis among household"/>
  <result pre="City, Aprilâ€“May 2009.J Infect Dis. 2010;201:984â€“9210.1086/65114520187740 10. collab: Centers for" exact="Disease" post="Control and PreventionIntroduction and transmission of 2009 pandemic influenza"/>
  <result pre="hundred (FF100) project. Epidemiological protocols for comprehensive assessment of early" exact="swine influenza" post="cases in the United Kingdom. 2009 May 28 [cited"/>
  <result pre="al.Effects of oseltamivir treatment on duration of clinical illness and" exact="viral" post="shedding and household transmission of influenza virus.Clin Infect Dis."/>
  <result pre="HeiderA, et al.Shedding and transmission of novel influenza virus A/H1N1" exact="infection" post="in householdsâ€”Germany, 2009.Am J Epidemiol. 2010;171:1157â€“6410.1093/aje/kwq07120439308 25. WelliverR, MontoAS,"/>
  <result pre="controlled trial.JAMA. 2001;285:748â€“5410.1001/jama.285.6.74811176912 26. LonginiIMJr, KoopmanJS, HaberM, CotsonisGAStatistical inference for" exact="infectious diseases." post="Risk-specific household and community transmission parameters.Am J Epidemiol. 1988;128:845â€“593421247"/>
  <result pre="2009: an observational study.Epidemiol Infect. 2010;138:183â€“9110.1017/S095026880999119119925691 29. collab: Centers for" exact="Disease" post="Control and PreventionSerum cross-reactive antibody response to a novel"/>
  <result pre="HardelidP, StanfordE, AndrewsN, ZambonMCIncidence of 2009 pandemic influenza A H1N1" exact="infection" post="in England: a cross-sectional serological study.Lancet. 2010;375:1100â€“810.1016/S0140-6736(09)62126-720096450 31. McClellanK,"/>
  <result pre="influenza virus.N Engl J Med. 2009;361:1945â€“5210.1056/NEJMoa090645319745214 33. HallCB, DouglasRGJrNosocomial influenza" exact="infection" post="as a cause of intercurrent fevers in infants.Pediatrics. 1975;55:673â€“71168894"/>
 </snippets>
</snippetsTree>
